Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of CDC25B was detected in 32 percent of human primary breast cancers tested.
|
7667636 |
1995 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression levels of CDC25B were generally higher than those of CDC25A and C. Of the 40 gastric carcinomas, 70% of the tumors expressed CDC25B mRNA at higher levels than the corresponding normal mucosas, while 38% overexpressed CDC25A mRNA.
|
9414655 |
1997 |
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Strong expression of CDC25B protein was associated with advanced stage and deep invasion.
|
9414655 |
1997 |
Carcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
The expression levels of CDC25B were generally higher than those of CDC25A and C. Of the 40 gastric carcinomas, 70% of the tumors expressed CDC25B mRNA at higher levels than the corresponding normal mucosas, while 38% overexpressed CDC25A mRNA.
|
9414655 |
1997 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Twenty-six of 35 (74%) lymphomas with high levels of cdc25B mRNA also showed c-myc overexpression, whereas 27 of 28 (96%) tumors without detectable or with very low cdc25B expression also had undetectable c-myc levels (P < 0.0001).
|
9563496 |
1998 |
Lymphoma
|
0.020 |
GeneticVariation
|
group |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
Adult Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
Childhood Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A biallelic EcoRI polymorphism of cdc25B gene was identified with a similar distribution in patients with lymphoma and in a normal population. cdc25A was overexpressed in three aggressive lymphomas.
|
9563496 |
1998 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Although Cdc25A and Cdc25B have been found to be over-expressed in many cancer cell lines and primary tumors, the physiological roles of Cdc25A and B in vivo are largely undefined.
|
10467401 |
1999 |
Esophageal carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the effect of CDC25B overexpression on radiation-induced G2-M arrest and radiation sensitivity in esophageal cancer cells.
|
11306507 |
2001 |
Esophageal Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In this study, we investigated the effect of CDC25B overexpression on radiation-induced G2-M arrest and radiation sensitivity in esophageal cancer cells.
|
11306507 |
2001 |
Malignant neoplasm of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
In this study, we investigated the effect of CDC25B overexpression on radiation-induced G2-M arrest and radiation sensitivity in esophageal cancer cells.
|
11306507 |
2001 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
CDC25A (+), as well as CDC25B (+), was more frequently found in patients with deeper tumour invasion and lymph node metastasis, while tumour size was correlated only with CDC25A expression.
|
11487274 |
2001 |
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
CDC25A (+), as well as CDC25B (+), was more frequently found in patients with deeper tumour invasion and lymph node metastasis, while tumour size was correlated only with CDC25A expression.
|
11487274 |
2001 |
Squamous cell carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of CDC25A and CDC25B expression in squamous cell carcinomas of the oesophagus.
|
11487274 |
2001 |
Secondary malignant neoplasm of lymph node
|
0.020 |
Biomarker
|
disease |
BEFREE |
CDC25A (+), as well as CDC25B (+), was more frequently found in patients with deeper tumour invasion and lymph node metastasis, while tumour size was correlated only with CDC25A expression.
|
11487274 |
2001 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The immunostaining results showed that Fra-1, Neogenin, Id-1, and CDC25B were overexpressed in both ESCC cell lines and their corresponding primary tumors at the protein level, validating the microarray findings.
|
11489794 |
2001 |
Squamous cell carcinoma of esophagus
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The immunostaining results showed that Fra-1, Neogenin, Id-1, and CDC25B were overexpressed in both ESCC cell lines and their corresponding primary tumors at the protein level, validating the microarray findings.
|
11489794 |
2001 |
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
To explain the atypical activation of Cdc2/cyclin B in degenerating neurons we have investigated the enzyme responsible for Cdc2/cyclin B activation in mitotic cells, i.e. the Cdc25B tyrosine phosphatase, in Alzheimer's disease brain.
|
11516829 |
2001 |
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, we suggest that cdc25B may play an active role as a target of N-myc in neuroblastoma, although the biological function of cdc25B in neuroblastoma remains to be clarified.
|
11689596 |
2001 |
Central neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, we suggest that cdc25B may play an active role as a target of N-myc in neuroblastoma, although the biological function of cdc25B in neuroblastoma remains to be clarified.
|
11689596 |
2001 |
Childhood Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
However, we suggest that cdc25B may play an active role as a target of N-myc in neuroblastoma, although the biological function of cdc25B in neuroblastoma remains to be clarified.
|
11689596 |
2001 |
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer.
|
12569365 |
2003 |
Malignant neoplasm of prostate
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP.
|
12569365 |
2003 |
Prostate carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Subsequently, we demonstrated that Cdc25B acts as a coactivator for AR in a hormone-dependent manner in the prostate cancer cell line, LNCaP.
|
12569365 |
2003 |